{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:24:13Z","timestamp":1789118653144,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Adelaide University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Methotrexate is a cornerstone disease-modifying antirheumatic drug for rheumatoid arthritis (RA), effectively controlling disease activity and reducing cardiovascular mortality. Despite its efficacy, parenteral methotrexate, which offers higher bioavailability, faster response, and fewer gastrointestinal side effects compared to oral administration, remains underutilized in clinical practice. Understanding the factors influencing its utilization is critical to improving RA management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore the barriers and enablers towards using parenteral methotrexate in rheumatoid arthritis patients from the perspective of Australian healthcare professionals (HCPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A qualitative study was conducted using semi-structured interviews between May and August 2022. Participants were recruited via advertising and snowballing. The Theoretical Domains Framework was used to guide the development of the interview guide and data analysis (directed content analysis), supplemented by conventional content analysis (inductive content analysis) to identify emergent themes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen HCPs (57.9% male, 42.1% female, 63.2% with more than 10\u00a0years of experience) were interviewed, including 14 rheumatologists, 3 pharmacists and 2 nurses. Findings related to domains \u201cenvironmental context and resources\u201d, \u201csocial influences\u201d and \u201cskills\u201d were frequently identified, whereas the domains \u201cintention\u201d, \u201creinforcement\u201d and \u201cemotion\u201d were least reported. The most prominent enablers related to HCPs' knowledge and skills. Necessary skills were grouped into communication, logistical planning, and patient selection. Other enablers included the accessibility of injection support services, availability of prefilled syringes and online resources for patients (\u201cenvironmental context and resources\u201d) and social influences. The most common identified barriers related to the logistics of implementing parenteral methotrexate. Other barriers included issues with the Occupational Health and Safety guidelines, time constraints (\u201cenvironmental context and resources\u201d), concerns about patients withdrawing methotrexate from the vial (\u201cemotion\u201d) and patients\u2019 low acceptability or affordability of the injectable medication (\u201csocial influences\u201d).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that training and guidance on selecting appropriate patients, utilization of systems to support education of patients and to minimize occupational exposure, and availability of patient-friendly devices would support greater implementation of parenteral methotrexate in practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02183-3","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:43:51Z","timestamp":1782859431000},"page":"2026-2037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Attitudes of healthcare professionals towards the use of parenteral methotrexate in rheumatoid arthritis patients: a qualitative study"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3660-6496","authenticated-orcid":false,"given":"Jiun Ming","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8184-4341","authenticated-orcid":false,"given":"Wern Chern","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6732-745X","authenticated-orcid":false,"given":"Nagham","family":"Ailabouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3046-9884","authenticated-orcid":false,"given":"Susanna M.","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3255-9242","authenticated-orcid":false,"given":"Michael D.","family":"Wiese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-999X","authenticated-orcid":false,"given":"Emily","family":"Reeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"suppl_6","key":"2183_CR1","doi-asserted-by":"publisher","first-page":"vi28","DOI":"10.1093\/rheumatology\/kes278","volume":"51","author":"KS Upchurch","year":"2012","unstructured":"Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford). 2012;51(suppl_6):vi28\u201336. https:\/\/doi.org\/10.1093\/rheumatology\/kes278.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2183_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000957.pub2","volume":"2014","author":"MA Lopez-Olivo","year":"2014","unstructured":"Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;2014(6):Cd000957. https:\/\/doi.org\/10.1002\/14651858.CD000957.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9313","key":"2183_CR3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","volume":"359","author":"HK Choi","year":"2002","unstructured":"Choi HK, Hern\u00e1n MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359(9313):1173\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)08213-2.","journal-title":"Lancet"},{"issue":"3","key":"2183_CR4","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","volume":"33","author":"G Bianchi","year":"2016","unstructured":"Bianchi G, Caporali R, Todoerti M, et al. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. Adv Ther. 2016;33(3):369\u201378. https:\/\/doi.org\/10.1007\/s12325-016-0295-8.","journal-title":"Adv Ther"},{"issue":"9","key":"2183_CR5","doi-asserted-by":"publisher","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, et al. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS ONE. 2019;14(9):e0221823-e. https:\/\/doi.org\/10.1371\/journal.pone.0221823.","journal-title":"PLoS ONE"},{"issue":"10","key":"2183_CR6","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1136\/ard.2009.124065","volume":"69","author":"MF Bakker","year":"2010","unstructured":"Bakker MF, Jacobs JW, Welsing PM, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. Ann Rheum Dis. 2010;69(10):1849\u201352. https:\/\/doi.org\/10.1136\/ard.2009.124065.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2183_CR7","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10067-013-2318-z","volume":"32","author":"R Fitzpatrick","year":"2013","unstructured":"Fitzpatrick R, Scott DG, Keary I. Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate. Clin Rheumatol. 2013;32(11):1605\u201312. https:\/\/doi.org\/10.1007\/s10067-013-2318-z.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2183_CR8","first-page":"42","volume":"10","author":"J Lee","year":"2017","unstructured":"Lee J, Pelkey R, Gubitosa J, et al. Comparing healthcare costs associated with oral and subcutaneous methotrexate or biologic therapy for rheumatoid arthritis in the United States. Am Health Drug Benefits. 2017;10(1):42\u20139.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"2183_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/rheumatology\/keh110","volume":"43","author":"AJ Griffin","year":"2004","unstructured":"Griffin AJ, Erkeller-Yuksel F. Parenteral methotrexate should be given before biological therapy. Rheumatology (Oxford). 2004;43(5):678. https:\/\/doi.org\/10.1093\/rheumatology\/keh110.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2183_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1002\/acr.23152","volume":"69","author":"MK Rohr","year":"2017","unstructured":"Rohr MK, Mikuls TR, Cohen SB, et al. Underuse of methotrexate in the treatment of rheumatoid arthritis: a national analysis of prescribing practices in the US. Arthritis Care Res (Hoboken). 2017;69(6):794\u2013800. https:\/\/doi.org\/10.1002\/acr.23152.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 2","key":"2183_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/imj.15302","volume":"51","author":"JA Ye","year":"2021","unstructured":"Ye JA, Sinnathurai P, Pulver L, et al. Patterns of use of b\/tsDMARDs and other medications for patients with rheumatoid arthritis: a retrospective study using PBS data. Intern Med J. 2021;51(Suppl 2):23. https:\/\/doi.org\/10.1111\/imj.15302.","journal-title":"Intern Med J"},{"issue":"6","key":"2183_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.reumae.2018.12.008","volume":"15","author":"J Tornero-Molina","year":"2019","unstructured":"Tornero-Molina J, Andreu JL, Mart\u00edn-Mart\u00ednez M-A, et al. Methotrexate in patients with rheumatoid arthritis in Spain: subanalysis of the AR excellence project. Reumatol Cl\u00edn (English Ed). 2019;15(6):338\u201342. https:\/\/doi.org\/10.1016\/j.reumae.2018.12.008.","journal-title":"Reumatol Cl\u00edn (English Ed)"},{"issue":"1","key":"2183_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12875-016-0574-0","volume":"18","author":"G Mas Dalmau","year":"2017","unstructured":"Mas Dalmau G, Sant Arderiu E, Enfedaque Montes MB, et al. Patients\u2019 and physicians\u2019 perceptions and attitudes about oral anticoagulation and atrial fibrillation: a qualitative systematic review. BMC Fam Pract. 2017;18(1):3. https:\/\/doi.org\/10.1186\/s12875-016-0574-0.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"2183_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1192\/apt.bp.114.013565","volume":"21","author":"P Bosanac","year":"2015","unstructured":"Bosanac P, Castle DJ. Why are long-acting injectable antipsychotics still underused? BJ Psych Adv. 2015;21(2):98\u2013105. https:\/\/doi.org\/10.1192\/apt.bp.114.013565.","journal-title":"BJ Psych Adv"},{"issue":"Suppl 2","key":"2183_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/imj.15302","volume":"51","author":"IS Hains","year":"2021","unstructured":"Hains IS, Hill C, Barrett C, et al. What do rheumatologists think and do in the management of inflammatory arthritis: a baseline survey. Intern Med J. 2021;51(Suppl 2):5\u201352. https:\/\/doi.org\/10.1111\/imj.15302.","journal-title":"Intern Med J"},{"issue":"2","key":"2183_CR16","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.3402\/qhw.v5i2.5146","volume":"5","author":"I Larsson","year":"2010","unstructured":"Larsson I, Bergman S, Fridlund B, et al. Patients\u2019 independence of a nurse for the administration of subcutaneous anti-TNF therapy: a phenomenographic study. Int J Qual Stud Health Well Being. 2010;5(2):5146. https:\/\/doi.org\/10.3402\/qhw.v5i2.5146.","journal-title":"Int J Qual Stud Health Well Being"},{"issue":"2","key":"2183_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1715163514521377","volume":"147","author":"C Bornstein","year":"2014","unstructured":"Bornstein C, Craig M, Tin D. Practice guidelines for pharmacists: the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Can Pharm J (Ott). 2014;147(2):97\u2013109. https:\/\/doi.org\/10.1177\/1715163514521377.","journal-title":"Can Pharm J (Ott)"},{"key":"2183_CR18","unstructured":"Australian Government Department of Health. Methotrexate 10 mg tablet, 50 [Internet]. Canberra: Pharmaceutical Benefits Scheme. Available from: https:\/\/www.pbs.gov.au\/medicine\/item\/11268C-11275K-11283W-11288D-11295L. Accessed 01 Aug 2023."},{"key":"2183_CR19","unstructured":"The Australian Pharmaceutical Benefits Scheme. Public Summary Document\u2014March 2017 PBAC Meeting [Internet]. 2017. https:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2017-03\/methotrexate-psd-march-2017. Accessed 01 Aug 2023."},{"key":"2183_CR20","unstructured":"European Medicines Agency. Methotrexate containing medicinal products [Internet]. Amsterdam: European Medicines Agency; 2019 [updated 21.10.2019]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/methotrexate-containing-medicinal-products. Accessed 03 Aug 2023."},{"key":"2183_CR21","unstructured":"IQVIA Consulting Services. Case studies for value added medicines: unlocking the potential of patient-centric continuous innovation [Internet]. Brussels: Medicines for Europe; 2019 Jan [updated 2019]. Available from: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2019\/04\/IQVIA-MFE_Case-Studies-for-VAMs_Final-Word-Document_vUpdate2019-v3.0.pdf. Accessed 02 Aug 2023."},{"issue":"9","key":"2183_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/acm.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, et al. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351. https:\/\/doi.org\/10.1097\/acm.0000000000000388.","journal-title":"Acad Med"},{"issue":"4","key":"2183_CR23","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","volume":"52","author":"B Saunders","year":"2018","unstructured":"Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893\u2013907. https:\/\/doi.org\/10.1007\/s11135-017-0574-8.","journal-title":"Qual Quant"},{"issue":"1","key":"2183_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13012-017-0605-9","volume":"12","author":"L Atkins","year":"2017","unstructured":"Atkins L, Francis J, Islam R, et al. A guide to using the theoretical domains framework of behaviour change to investigate implementation problems. Implement Sci. 2017;12(1):77. https:\/\/doi.org\/10.1186\/s13012-017-0605-9.","journal-title":"Implement Sci"},{"issue":"7","key":"2183_CR25","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1245\/s10434-018-6466-x","volume":"25","author":"JS Lee","year":"2018","unstructured":"Lee JS, Parashar V, Miller JB, et al. Opioid prescribing after curative-intent surgery: a qualitative study using the theoretical domains framework. Ann Surg Oncol. 2018;25(7):1843\u201351. https:\/\/doi.org\/10.1245\/s10434-018-6466-x.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2183_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13012-015-0349-3","volume":"10","author":"CA Cadogan","year":"2015","unstructured":"Cadogan CA, Ryan C, Francis JJ, et al. Improving appropriate polypharmacy for older people in primary care: selecting components of an evidence-based intervention to target prescribing and dispensing. Implement Sci. 2015;10(1):161. https:\/\/doi.org\/10.1186\/s13012-015-0349-3.","journal-title":"Implement Sci"},{"issue":"1","key":"2183_CR27","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1186\/s12889-019-7442-5","volume":"19","author":"F Cowdell","year":"2019","unstructured":"Cowdell F, Dyson J. How is the theoretical domains framework applied to developing health behaviour interventions? A systematic search and narrative synthesis. BMC Public Health. 2019;19(1):1180. https:\/\/doi.org\/10.1186\/s12889-019-7442-5.","journal-title":"BMC Public Health"},{"issue":"4","key":"2183_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4103\/0976-0105.14194229","volume":"5","author":"S Jamshed","year":"2014","unstructured":"Jamshed S. Qualitative research method-interviewing and observation. J Basic Clin Pharm. 2014;5(4):87\u20138. https:\/\/doi.org\/10.4103\/0976-0105.14194229.","journal-title":"J Basic Clin Pharm."},{"issue":"9","key":"2183_CR29","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"13","key":"2183_CR30","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360. https:\/\/doi.org\/10.1177\/1049732315617444.","journal-title":"Qual Health Res"},{"key":"2183_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25141","author":"JM Tan","year":"2023","unstructured":"Tan JM, Reeve E, Fraser L, et al. The barriers and enablers to the use of parenteral methotrexate in rheumatoid arthritis patients: a scoping review. Arthritis Care Res (Hoboken). 2023. https:\/\/doi.org\/10.1002\/acr.25141.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"2183_CR32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11096-025-02023-w","volume":"48","author":"JM Tan","year":"2026","unstructured":"Tan JM, Desforges K, Chai WC, Proudman SM, Wiese MD, Reeve E. Perspectives of patients with rheumatoid arthritis towards the use of parenteral methotrexate: a qualitative study. Int J Clin Pharm. 2026;48(2):557\u201368. https:\/\/doi.org\/10.1007\/s11096-025-02023-w.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"2183_CR33","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12913-021-07459-0","volume":"22","author":"MJH Voshaar","year":"2022","unstructured":"Voshaar MJH, van den Bemt BJF, van de Laar MAFJ, et al. Healthcare professionals\u2019 perceptions on barriers and facilitators to DMARD use in rheumatoid arthritis. BMC Health Serv Res. 2022;22(1):62. https:\/\/doi.org\/10.1186\/s12913-021-07459-0.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2183_CR34","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10067-010-1383-9","volume":"29","author":"S Bernatsky","year":"2010","unstructured":"Bernatsky S, Feldman D, De Civita M, et al. Optimal care for rheumatoid arthritis: a focus group study. Clin Rheumatol. 2010;29(6):645\u201357. https:\/\/doi.org\/10.1007\/s10067-010-1383-9.","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2183_CR35","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/1756-185X.13660","volume":"22","author":"P Heidari","year":"2019","unstructured":"Heidari P, Cross W, Weller C, et al. Rheumatologists\u2019 insight into medication adherence in patients with rheumatoid arthritis: a qualitative study. Int J Rheum Dis. 2019;22(9):1695\u2013705. https:\/\/doi.org\/10.1111\/1756-185X.13660.","journal-title":"Int J Rheum Dis"},{"key":"2183_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.2147\/ppa.S101175","volume":"10","author":"A Ganguli","year":"2016","unstructured":"Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711\u201325. https:\/\/doi.org\/10.2147\/ppa.S101175.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2183_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2125.2012.04366.x","volume":"74","author":"L Bate","year":"2012","unstructured":"Bate L, Hutchinson A, Underhill J, et al. How clinical decisions are made. Br J Clin Pharmacol. 2012;74(4):614\u201320. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04366.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2183_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.hrtlng.2006.08.005","volume":"36","author":"D Quiros","year":"2007","unstructured":"Quiros D, Lin S, Larson EL. Attitudes toward practice guidelines among intensive care unit personnel: a cross-sectional anonymous survey. Heart Lung. 2007;36(4):287\u201397. https:\/\/doi.org\/10.1016\/j.hrtlng.2006.08.005.","journal-title":"Heart Lung"},{"issue":"4","key":"2183_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1177\/0149206309352880","volume":"36","author":"BD Blume","year":"2010","unstructured":"Blume BD, Ford JK, Baldwin TT, et al. Transfer of training: a meta-analytic review. J Manag. 2010;36(4):1065\u2013105. https:\/\/doi.org\/10.1177\/0149206309352880.","journal-title":"J Manag"},{"key":"2183_CR40","unstructured":"Lim I. Ridiculous things said about methotrexate [Internet]. Sydney: BJC Health; 2013. Available from: https:\/\/www.bjchealth.com.au\/connected-care\/2013\/03\/ridiculous-things-said-about-methotrexate\/. Accessed 03 Aug 2023."},{"issue":"10","key":"2183_CR41","doi-asserted-by":"publisher","first-page":"440","DOI":"10.5694\/mja16.00965","volume":"205","author":"MH Arnold","year":"2016","unstructured":"Arnold MH, Bleasel J, Haq I. Nocebo effects in practice: methotrexate myths and misconceptions. Med J Aust. 2016;205(10):440\u20132. https:\/\/doi.org\/10.5694\/mja16.00965.","journal-title":"Med J Aust"},{"key":"2183_CR42","unstructured":"Council of Australian Therapeutic Advisory Groups. Supporting safe practices for low-dose methotrexate: position statement on the use of low-dose methotrexate [Internet]. Darlinghurst (NSW): CATAG; 2020 Oct. Available from: https:\/\/catag.org.au\/wp-content\/uploads\/CATAG-Position-Statement-on-the-use-of-low-dose-methotrexate-1-1.pdf. Accessed 03 Aug 2023."},{"key":"2183_CR43","unstructured":"Royal College of Nursing. Administering subcutaneous methotrexate for inflammatory arthritis [Internet]. 4th ed. London: Royal College of Nursing; 2021. (Publication code: 009 675). Available from: https:\/\/www.rcn.org.uk\/-\/media\/Royal-College-Of-Nursing\/Documents\/Publications\/2021\/October\/009-675.pdf. Accessed 03 Aug 2023."},{"issue":"5","key":"2183_CR44","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/17434440.2014.929492","volume":"11","author":"M Schiff","year":"2014","unstructured":"Schiff M, Jaffe J, Freundlich B, et al. New autoinjector technology for the delivery of subcutaneous methotrexate in the treatment of rheumatoid arthritis. Expert Rev Med Devices. 2014;11(5):447\u201355. https:\/\/doi.org\/10.1586\/17434440.2014.929492.","journal-title":"Expert Rev Med Devices"},{"issue":"1","key":"2183_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1748-5908-6-42","volume":"6","author":"S Michie","year":"2011","unstructured":"Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42. https:\/\/doi.org\/10.1186\/1748-5908-6-42.","journal-title":"Implement Sci"},{"issue":"1","key":"2183_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1289-z","volume":"17","author":"M Voshaar","year":"2016","unstructured":"Voshaar M, Vriezekolk J, van Dulmen S, et al. Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskelet Disord. 2016;17(1):442. https:\/\/doi.org\/10.1186\/s12891-016-1289-z.","journal-title":"BMC Musculoskelet Disord"},{"issue":"7","key":"2183_CR47","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/acr.24596","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924\u201339. https:\/\/doi.org\/10.1002\/acr.24596.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"2183_CR48","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10067-010-1500-9","volume":"29","author":"H Mainman","year":"2010","unstructured":"Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate? Clin Rheumatol. 2010;29(10):1093\u20138. https:\/\/doi.org\/10.1007\/s10067-010-1500-9.","journal-title":"Clin Rheumatol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02183-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:10Z","timestamp":1789117090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02183-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":48,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2183"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02183-3","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Declaration of Helsinki. The Central Adelaide Local Health Network (CALHN) Human Research Ethics Committee and University of South Australia's Human Research Ethics Committee have approved the research protocol and written informed consent was obtained from the subjects.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the subjects included in this study.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}